CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachusetts has been granted, relocating the case to the Eastern District of Virginia. This transfer is expected to expedite the progress of the litigation significantly and potentially lead to a trial date as early as 2024.

In pre-market trading, $CVAC is currently valued at $8.92, showing an increase of $0.16 (+1.83%).

Ambrx Biopharma Inc. (Nasdaq: AMAM) has been initiated with an Overweight rating and a price target of $25 by Cantor Fitzgerald.

$AMAM is currently trading at $13.80 in pre-market, experiencing a slight increase of $0.03 (+0.22%).

Additionally, Legend Biotech Corporation (Nasdaq: LEGN) has received a price target raise from Barclays, with the target being increased from $65 to $90.

In pre-market trading, $LEGN is currently trading at $70.09, reflecting an increase of $1.15 (+1.67%).

Please note that the stock prices and pre-market movements mentioned here are for illustrative purposes and may not reflect the current market conditions at the time of reading.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)